Pfizer hands Phase II-stage TB drug candidate to Sequella
This article was originally published in Scrip
Executive Summary
Pfizer has out-licensed sutezolid, its Phase II-stage oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB), to privately held US firm Sequella.